Give ‘em points for creativity - micro cap company Immunosyn Corporation (IMYN) has submitted photos to the SEC as part an official filing. Pictures of what? They called them ‘proof of concept’ for a biopharmaceutical treatment of diabetic ulcers. The photos were of - you guessed it - the open wounds of diabetic patients. Weird to be sure, but apparently effective…the stock is up 22% today.

The photos are just the beginning of what the company intends to become a wider scale version of the same efficacy test. After that test is complete, a full-scale clinical trial is planned at a major wound clinic in Europe.

There was no mention of testing or commercialization in the United States. However, that’s not a surprise - the United States’ FDA tends to be less progressive than overseas regulators, even for minor treatment options such as this one.

Though Immunosyn is likely to expand into the U.S. if and when the opportunity arises, it does not appear as if that’s the focus right now. Of course, it doesn’t need to be - the majority of the world lives outside the United States, and there’s plenty of marketability for a product like this.

From the same official document filed with the photographs, Immunosyn said “According to the International Diabetes Federation (IDF), globally, an approximated 246 million people have Diabetes Mellitus, of which one in six will develop a diabetic foot ulcer. Also according to IDF, extensive epidemiological surveys indicate that between 40% and 70% of all lower extremity amputations are related to diabetes and that every 30 seconds a leg is lost to diabetes somewhere in the world.”

Investors seemed to like the pictures, and the opportunity.